China → Europe & US life-science consulting

Your bridge to Europe and US life sciences.

We help Chinese life science companies plan European and US market entry, connecting regulatory strategy, clinical development, quality and evidence planning under one accountable founder.

Why Kaiveo Medical exists

A clear plan from Chinese innovation to European and US markets.

European and US pathways differ in their evidence requirements, agency procedures and payer expectations. We help China-based teams understand those differences, assess their existing data and plan the work needed for their product.

One founder leads your engagement, connecting regulatory, clinical, quality and medical evidence questions within an agreed scope. Quality and payer-evidence planning start early, alongside the regulatory strategy.

About Kaiveo Medical
01

One integrated partner

Regulatory, clinical, quality and evidence planning follow one coordinated roadmap, with clear responsibilities and decisions shared across workstreams.

02

Depth in both systems

Hands-on experience informs our assessment of EU and FDA requirements, from clinical trial applications and medicines dossiers to quality and device pathways. Each engagement is matched to the expertise it needs.

03

Fluent in both worlds

We explain scientific and regulatory expectations in the context of your programme. Language support is agreed for each engagement.

The China → Europe & US journey

A structured path from first assessment to growth in both markets.

Five stages, one coordinated roadmap. Quality, risk management and payer-evidence planning run across the stages. Select a stage to explore the work and its intended deliverables.

CNStart in ChinaYour headquarters, your science
Plan for Europe and the USAuthorisation, compliance and launchEUUS
Stage 01 · Assess

Know the route before you commit the budget.

We review your product, data, manufacturing arrangements and target markets. Regulatory options, quality gaps and clinical or payer-evidence questions are assessed together, so the roadmap reflects the work, budget assumptions and risks specific to your programme.

What you receive

  • Market & competitor landscape, both regions
  • Regulatory gap analysis of your existing package
  • Country prioritisation & sequencing
  • Integrated budget, timeline & risk register
Stage 02 · Prepare

Choose the pathway and build the case for it.

For medicines, we distinguish EU clinical trial applications from marketing authorisation routes, and US INDs from full NDAs, 505(b)(2) NDAs, ANDAs and BLAs. For devices and IVDs, we assess the applicable conformity or FDA route. Briefing documents, agency preparation and an evidence-gap plan support the selected strategy.

What you receive

  • Regulatory strategy & procedure selection
  • Scientific advice / notified body briefing packages
  • CTA / IND, eCTD or technical documentation gap plan
  • Submission plan with agency interaction calendar
Stage 03 · Prove

Build evidence for the intended regulatory pathway.

We assess study design, endpoints, comparators, populations and country options against the intended use of the data. Carefully selected CROs and sites support an agreed oversight plan. Regulatory Affairs coordinates CTA or IND submissions; device investigations and IVD performance studies follow their applicable procedures.

What you receive

  • EU- and US-ready clinical development plan
  • Study start-up and regulatory filing coordination
  • CRO / vendor selection and contract oversight
  • Data & documentation ready for review
Stage 04 · Comply

Make quality a strength, not a risk.

Quality preparation begins during assessment and continues through development. We review applicable requirements, investigate gaps, support CAPA effectiveness and prepare staff for inspections. Where a QP, QPPV, authorised representative, PRRC or US Agent is required, responsibilities and the need for an appropriately qualified provider are identified before any appointment is agreed.

What you receive

  • QMS gap assessment & remediation plan
  • Mock inspections & CAPA support
  • Supplier / CDMO qualification
  • Specialist-role requirements and appointment planning
Stage 05 · Launch & grow

Approval is the beginning. Adoption is the goal.

We connect the regulatory evidence plan with clinical and payer questions early in development. Authorisation, pricing and reimbursement are separate objectives. The launch roadmap identifies scientific communication, post-market evidence and specialist support needs, with delivery responsibilities and scope agreed for the engagement.

What you receive

  • Medical launch plan & scientific platform
  • Clinical and payer evidence priorities
  • Post-market evidence and vigilance requirements
  • Lifecycle & multi-country expansion roadmap

See the full market-entry programme

Your existing data

How far does your Chinese evidence travel?

EU and US authorities assess the evidence for the application before them. We review the quality, relevance and regulatory fit of your existing Chinese data, then identify what can support the submission and where further work may be needed.

Pharma

We assess whether your Chinese CMC, non-clinical and clinical evidence can support the intended EU or FDA application, considering study quality, population relevance and the remaining gaps.

Biotech

We assess biologic and ATMP evidence, including CMC, comparability and clinical data, against the intended EU or FDA pathway and identify where further justification or development may be needed.

Medical devices & IVD

We distinguish device clinical evaluation from IVD performance evaluation, assessing whether existing data support the intended claims and identifying evidence gaps for CE marking or FDA submissions.

Why Kaiveo Medical

Built for the China–Europe–US corridor, not adapted to it.

Kaiveo Medical focuses on the practical needs of China-based teams planning European and US development. A named founder keeps the scope, priorities and responsibilities clear.

Remote, founder-led consulting

A remote consultancy with one accountable founder as your lead. Meeting arrangements, reporting and language support are agreed for each engagement.

  • Remote delivery, with on-site visits by arrangement.
  • Scope and schedule agreed per engagement.

End-to-end accountability

One founder coordinates the agreed work, records decisions and maintains clear responsibilities across the programme.

Relevant experience

Your engagement is matched to the relevant regulatory, clinical or quality experience, with specialist requirements identified during scoping.

Regulatory intelligence

We review relevant EU and FDA developments for the agreed scope and explain what changes may mean for your evidence, submission or quality plan.

Clear scope and delivery

From a dossier review to a coordinated market-entry programme, deliverables, availability and milestones are agreed before work begins.

Appropriate specialist support

We identify where CRO, legal, market-access or other specialist input is needed. Provider availability, qualifications and responsibilities are confirmed before appointments are made.

Industries

Specialised support for every product type.

Pharmaceuticals

Innovative, generic and biosimilar medicines

Pathway: Existing data → EU authorisation via EMA or national authorities; FDA NDA, ANDA or BLA. Clinical trials use separate CTA / IND pathways.

We prepare manufacturing sites for EU GMP inspection and assess dossiers against the intended EU or FDA route, including drug-led combination products. Biotechnology-derived biosimilars require the EU centralised procedure; other products are assessed for the appropriate route.

  • EU MAA strategy: centralised, DCP / MRP or national routes
  • EU GMP and FDA cGMP readiness for Chinese sites
  • QP, import and US Agent requirements assessment
Pharma services
Biotechnology

Biologics, ATMPs and novel modalities

Pathway: EU CTA / FDA IND where required → development evidence → EU or FDA marketing application.

Cell and gene therapies, antibodies, bispecifics, RNA platforms: European reviewers scrutinise novel modalities closely, and early dialogue matters. We help biotech innovators secure the right designations, engage EMA early and design clinical programmes that European regulators and clinicians trust.

  • Scientific advice, orphan designation and PRIME eligibility
  • ATMP-specific regulatory and GMP considerations
  • First-in-human and pivotal study set-up in Europe and the US
Biotech services
Medical Devices & IVDs

MDR, IVDR and FDA conformity, done properly

Pathway: EU MDR / IVDR conformity assessment for CE marking; FDA 510(k) clearance, De Novo classification or PMA approval.

CE marking under the MDR and IVDR requires technical documentation, device clinical evaluation or IVD performance evaluation, and an appropriate quality system. We assess classification, conformity route, evidence gaps and post-market requirements for the specific product.

  • Classification, conformity route and notified-body strategy
  • Technical documentation and device / IVD evidence requirements
  • ISO 13485 QMS alignment and audit readiness
Medical device services
Start the conversation

Ready to bring your innovation to European and American patients?

Tell us about your product, development stage and target markets. We can discuss the regulatory, clinical, quality and evidence questions that should shape the next step.

WeChat QR code

Add us on WeChat for a direct conversation

Check your readiness for either market.

We aim to reply within two working days. Language support is agreed for each engagement.

One founder leads each engagement. Specialist appointments and delivery responsibilities are scoped separately.